DexaDagen-2 study
Completed
- Conditions
- Acute lymphoblastic leukemia, behavior, sleep, mood, quality of life, frailty
- Registration Number
- NL-OMON22781
- Lead Sponsor
- Princes Maxima Centre for pediatric oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 105
Inclusion Criteria
Written informed consent
- Age 3-18
Exclusion Criteria
- Patient or parent refusal
- Anticipated compliance problems
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eurobehavioral problems after 5 days of dexamethasone treatment with or without hydrocortisone addition. These neurobehavioral problems will be measured with the parent-reported SDQ.
- Secondary Outcome Measures
Name Time Method